About Y-Biologics
Y-Biologics is a company based in Daejeon (South Korea) founded in 2007.. Y-Biologics has raised $42.1 million across 3 funding rounds from investors including DSC Investment, Aju IB Investment and Miraeassetsecuritiesus. The company has 58 employees as of December 31, 2024. Y-Biologics offers products and services including Ymax®-ABL, ALiCE, and pH-Sensitive Antibodies. Y-Biologics operates in a competitive market with competitors including GenScript, Sino Biological, Epitomics, Mabtech and Shanghai OPM Biosciences, among others.
- Headquarter Daejeon, South Korea
- Employees 58 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Y-Biologics Inc.
-
Annual Revenue
$3.91 M (USD)65.64as on Dec 31, 2024
-
Net Profit
$-4.37 M (USD)69.14as on Dec 31, 2024
-
EBITDA
$-4.35 M (USD)17.71as on Dec 31, 2024
-
Total Equity Funding
$42.1 M (USD)
in 3 rounds
-
Latest Funding Round
$25.2 M (USD), Post-IPO
Aug 08, 2025
-
Investors
DSC Investment
& 9 more
-
Employee Count
58
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Y-Biologics
Y-Biologics is a publicly listed company on the KRX with ticker symbol 338840 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Y-Biologics
Y-Biologics offers a comprehensive portfolio of products and services, including Ymax®-ABL, ALiCE, and pH-Sensitive Antibodies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for discovering fully human antibodies for therapeutics.
Enables T-cell activation for enhanced cancer cell destruction.
Targets cancer cells specifically to reduce normal tissue toxicity.
Funding Insights of Y-Biologics
Y-Biologics has successfully raised a total of $42.1M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25.2 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $25.2M
-
First Round
First Round
(01 Apr 2016)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2025 | Amount | Post-IPO - Y-Biologics | Valuation |
investors |
|
| Nov, 2018 | Amount | Series C - Y-Biologics | Valuation |
investors |
|
| Apr, 2016 | Amount | Series A - Y-Biologics | Valuation | InterVest |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Y-Biologics
Y-Biologics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include DSC Investment, Aju IB Investment and Miraeassetsecuritiesus. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Dayli Partners is focused on bio-healthcare and fintech investments.
|
Founded Year | Domain | Location | |
|
Private equity investment firm focused on buyouts
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on tech startups
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Y-Biologics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Y-Biologics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Y-Biologics Comparisons
Competitors of Y-Biologics
Y-Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenScript, Sino Biological, Epitomics, Mabtech and Shanghai OPM Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Reagents and instruments are provided for life sciences research.
|
|
| domain | founded_year | HQ Location |
Reagents and kits are provided for clinical research applications.
|
|
| domain | founded_year | HQ Location |
Monoclonal antibody technology and products are developed by Epitomics.
|
|
| domain | founded_year | HQ Location |
Antibodies and immunoassay kits are developed for research applications.
|
|
| domain | founded_year | HQ Location |
Antibody and vaccine culture media products are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Y-Biologics
Frequently Asked Questions about Y-Biologics
When was Y-Biologics founded?
Y-Biologics was founded in 2007 and raised its 1st funding round 9 years after it was founded.
Where is Y-Biologics located?
Y-Biologics is headquartered in Daejeon, South Korea.
Is Y-Biologics a funded company?
Y-Biologics is a funded company, having raised a total of $42.1M across 3 funding rounds to date. The company's 1st funding round was a Series A of $9M, raised on Apr 01, 2016.
How many employees does Y-Biologics have?
As of Dec 31, 2024, the latest employee count at Y-Biologics is 58.
What is the annual revenue of Y-Biologics?
Annual revenue of Y-Biologics is $3.91M as on Dec 31, 2024.
What does Y-Biologics do?
Developer of antibodies for the treatment of multiple diseases. It has designed a proprietary technology to develop the antibody for therapeutic application. The company has secured a set of cDNA libraries and a set of receptor libraries for the selection of the antibody and new target discovery and evaluation. It has also developed a proprietary transient HEK293 system for transfection and protein production. Additionally, the company offers several antibody-related services.
Who are the top competitors of Y-Biologics?
Y-Biologics's top competitors include Sino Biological, GenScript and Shanghai OPM Biosciences.
What products or services does Y-Biologics offer?
Y-Biologics offers Ymax®-ABL, ALiCE, and pH-Sensitive Antibodies.
Is Y-Biologics publicly traded?
Yes, Y-Biologics is publicly traded on KRX under the ticker symbol 338840.
Who are Y-Biologics's investors?
Y-Biologics has 10 investors. Key investors include DSC Investment, Aju IB Investment, Miraeassetsecuritiesus, Dayli Partners, and Smile Gate Investment.
What is Y-Biologics's ticker symbol?
The ticker symbol of Y-Biologics is 338840 on KRX.